BAX 855 Dose-Escalation Safety Study

Inclusion Criteria: * The subject is male and is 18 to 65 years of age at the time of screening * The subject has severe hemophilia A (factor VIII level \< 1%) * The subject was previously treated with plasma-derived factor VIII (FVIII) concentrates or recombinant FVIII for at least 150 exposure days (EDs) Exclusion Criteria: * The subject has a detectable FVIII inhibitor at screening, with a titer \>= 0.6 BU * The subject has a documented history of FVIII inhibitors with a titer \>= 0.4 BU at any time prior to screening * The subject has a known hypersensitivity towards mouse or hamster proteins or to polyethylene glycol (PEG)